Anda di halaman 1dari 2

Title: Abdominal Chemo Increases Ovarian Cancer Survival Rate Word Count: 638 Summary: A large clinical test

shows that giving chemotherapy directly into the stomach, as well as into a vein, can improve survival of women with advanced ovarian canc er by about sixteen months. The results of the study, which pop up in this week' s issue of the New England Journal of Medicine, prompted the National Cancer Ins titute to issue a statement supporting doctors to employ this plan of attack for appropriate patients. Keywords: cancer Article Body: A large clinical test shows that giving chemotherapy directly into the stomach, as well as into a vein, can improve survival of women with advanced ovarian canc er by about sixteen months. The results of the study, which pop up in this week' s issue of the New England Journal of Medicine, prompted the National Cancer Ins titute to issue a statement supporting doctors to employ this plan of attack for appropriate patients. Why is this new treatment reigmine so important? Ovarian cancer is the fourth gr eatest reason of cancer demises in women, affecting more than 22,000 women and k illing more than 16,000 in 2005. Although this disease is super treatable when s aw ahead of time, virtually all cases are not noticed until they have dispersed beyond the ovaries. Because so many ovarian cancer patients are diagnosed at a l ater stage, it is crucial to find ways to better treatments for further progress ed disease. What is already known about ovarian cancer? virtually all women with advanced ov arian cancer get chemotherapy after surgery to get rid of the tumor. That chemot herapy is usually given into a vein and moves through the bloodstream to reach t umor cells in the stomach. Doctors have also experimented with rendering the che motherapy straight into the abdomen through a catheter, a system called intraper itoneal (IP) chemotherapy. Eight clinical trials of this approach have been done , and most showed a gain to IP chemotherapy. But this technique is not widely wo re, according to the study's author, Deborah Armstrong, MD. "There has been a prejudice against IP therapy in ovarian cancer because it's an old idea, it requires skill and experience for the surgery and for the chemothe rapy, and it's additional complicated than IV chemotherapy," said Armstrong, who is a medical oncologist and associate professor at the John Hopkins Kimmel Canc er Center in Baltimore. How this study was done: Women with stage III ovarian cancer were randomly assig ned to get either standard chemotherapy in a vein (210 women), or a combination of chemotherapy in a vein and IP chemotherapy (205 women). The women had already had surgery that successfully removed all or most of the tumor; none had tumors remaining that were larger than 1 cm in diameter. All the women were treated wi th the same drugs, cisplatin and paclitaxel. Six cycles of chemotherapy were pla nned for both groups. What was found? Women who had IP chemo operated long without their cancer coming back and lived longest overall. Women who had traditional chemotherapy in a vei

n survived about 4 years after treatment, while those who got chemotherapy in th e stomach as well as a vein stomach an median of nearly 5 years after treatment. That improvement is "one of the largest benefits ever observed for a new therapy in gynecologic oncology," based on data from Stephen A. Cannistra, MD, who comp osed an editorial published with the study. He is a professor at Harvard Medical School and managing director of the division of gynecologic medical oncology at Beth Israel Deaconess Medical Center in Boston. Nonetheless, the IP treatment was very much more difficult on the patients. Wome n who had this treatment had many additional terrible or life-threatening side e ffects, including low white blood cell counts, infection, tiredness, and anguish . Many side effects were associated to the catheters that must be introduced int o the stomach to deliver the chemotherapy. These problems were so serious that f ewer than half of the women designated to undergo IP chemotherapy finished all s ix designed treatment cycles. That makes the survival advance that good deal sup plementary noteworthy, Cannistra composed. Women who got IP therapy also reported significantly worse caliber of life durin g and just after treatment. By one year out, nonetheless, both groups described similar quality of life. Discover the best <a href="http://www.cancercuretruth.com/">alternative cancer t reatments</a>!</p> SEO Solutions and <a href="http://www.linkacquire.com/">one way link </a> public ity services provided by LinkAcquire.